FindTrial
Sign In

Investigation of tolerablity & effectiveness of Bromocriptine in comparison with Teneligliptin in patients diagnosed with type II diabetes mellitus

Assessment of safety & efficacy of Bromocriptine in comparison with Teneligliptin in newly diagnosed type II diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013591
Enrollment
50
Registered
2018-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- type 2 diabetes mellitus Health Condition 2: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Bromocriptine: 0.8 mg dose initially and escalated to 1.6 mg after 15 days. Total duration of treatment is 3 months.Dose to be taken as OD before breakfast within 2 hrs after waking up

Sponsors

Nasrin Nisha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed type 2 DM FBS between 140 mg/dl and 240 mg/dl PPBS between 200 mg/dl and 350 mg/dl Hb1Ac between 7% &10% BMI between 22 and 40 kg/m2

Exclusion criteria

Exclusion criteria: Patients with complications of DM Pregnant & nursing women Patients with known hypersensitivity to Bromocriptine or ergot related compounds or Teneligliptin. Patients with migraine. Patients with H/O significant systemic disorders

Design outcomes

Primary

MeasureTime frame
Fasting Blood sugar and Post prandial blood sugarTimepoint: at baseline and thereafter every 3 months—

Secondary

MeasureTime frame
HbA1cTimepoint: at baseline and thereafter every month for 3 months—

Countries

India

Contacts

Public ContactNasrin Nisha

Chettinad Hospital and Research Institute

arunrmbbs1978@gmail.com9884212644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026